Molecular profiling and target actionability for precision medicine in neuroendocrine neoplasms: real-world data - Institut Gustave Roussy
Article Dans Une Revue European Journal of Cancer Année : 2023

Molecular profiling and target actionability for precision medicine in neuroendocrine neoplasms: real-world data

Résumé

Background: Key molecular alterations (MA) of neuroendocrine neoplasm (NEN) of various grade/primaries have been described but the applicability of molecular profiling (MP) for precision medicine in NEN remains to be demonstrated. Methods: We conducted a retrospective study of all patients with metastatic NEN who had MP on tumour tissue at Gustave Roussy. The primary objective was to assess the clinical applicability of MP by evaluating the growth modulator index (GMI) as the primary end-point. Results: MPs were obtained in 114 out of 156 eligible patients, including 12% NET-G1, 42% NET-G2, 13% NET-G3 and 35% neuroendocrine carcinoma (NEC). Primary sites were lung/thymus (40%), pancreas (19%), gastro-intestinal (16%), head&neck (10%), unknown (10%) and others (10%) with synchronous metastases in 61% of the patients. Most frequent MA were: MEN1 (25%), PTEN (13%), TP53 (11%) and TSC2 (9%), in neuroendocrine tumour (NET), and TP53 (50%) and RB1 (18%) in NEC. ESMO Scale for Clinical Actionability of Molecular Targets (ESCAT) classification of these MA were: I(5%), III(20%), IV(23%), X(27%); a putative actionable MA was identified in 48% patients. Median TMB was 5.7 Mut/Mb, with 3 TMB > 10 and 1 MSI NET. No MA was found in 26% patients. Molecularly matched treatment was administered to 19 patients (4 NEC, 15 NET): immunotherapy (n = 3), tipifarnib (n = 1), NOTCHi (n = 1), EGFRi (n = 2), HER2i (n = 1) and everolimus (n = 11). Overall, 67% of patients had a clinical benefit defined as a GMI over 1.3 with a 78% disease control rate. Conclusion: We report 48% of NEN with a putative actionable MA of which 35% received molecularly matched treatment, with a clinical benefit in 67% of the cases.
Fichier principal
Vignette du fichier
2023_Faron_Bayle_EurJCancer.pdf (896.16 Ko) Télécharger le fichier
Origine Fichiers produits par l'(les) auteur(s)

Dates et versions

hal-04106320 , version 1 (09-04-2024)

Identifiants

Citer

Alice Boilève, Matthieu Faron, Sarah Fodil-Cherif, Arnauld Bayle, Livia Lamartina, et al.. Molecular profiling and target actionability for precision medicine in neuroendocrine neoplasms: real-world data. European Journal of Cancer, 2023, 186, pp.122-132. ⟨10.1016/j.ejca.2023.03.024⟩. ⟨hal-04106320⟩
101 Consultations
47 Téléchargements

Altmetric

Partager

More